Your new experience awaits. Try the new design now and help us make it even better

SYSTEMATIC REVIEW article

Front. Pharmacol.

Sec. Pharmacology of Anti-Cancer Drugs

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1600892

Comparative long-term outcomes of First-line CDK4/6 inhibitors plus endocrine therapy versus endocrine therapy in patients with HR+/HER2-metastatic or advanced breast cancer: a meta-analysis

Provisionally accepted
Xiaojian  WangXiaojian WangXinyi  LiangXinyi LiangMengtian  QinMengtian QinJianyu  WuJianyu WuYuechen  QinYuechen QinYue  ZouYue ZouHaijian  ZengHaijian ZengChunlan  LiChunlan LiXiaomeng  HuangXiaomeng HuangHaiyun  TaoHaiyun TaoXiao  WangXiao Wang*
  • Guangxi University of Science and Technology, Liuzhou, China

The final, formatted version of the article will be published soon.

Introduction This meta-analysis was designed to compare the long-term outcomes of first-line cyclin-dependent kinase 4/6 (CDK4/6) inhibitors plus endocrine therapy (ET) versus ET in patients with HR+/HER2-metastatic or advanced breast cancer (BC).Four databases (Medline, Embase, Web of Science, and CENTRAL) were searched for literature comparing First-line CDK4/6 inhibitors plus ET to ET in patients with HR+/HER2metastatic or advanced breast cancer. The search was conducted from the database's establishment to April 3, 2025. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and severe treatment-related adverse events (SAEs) were subjected to meta-analyses.Twelve Randomized controlled trials (RCTs) were included in the meta-analysis. The meta-analysis included a group of 4957 patients diagnosed with HR+/HER2-metastatic or advanced breast cancer. Within this cohort, 2877 patients were administered First-line CDK4/6 inhibitors together with ET, while 2080 patients received first-line ET alone. Compared with ET, First-line CDK4/6 inhibitors plus ET yielded

Keywords: breast cancer, Metastatic, Endocrine therapy, CDK4/6 inhibitors, Progression-free survival, overall survival, Objective response rate, Meta-analysis

Received: 27 Mar 2025; Accepted: 16 Jul 2025.

Copyright: © 2025 Wang, Liang, Qin, Wu, Qin, Zou, Zeng, Li, Huang, Tao and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Xiao Wang, Guangxi University of Science and Technology, Liuzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.